Since newly emerging biomarkers such as neutrophil gelatinase-associated lipocalin (NGAL) and interleukin-18 have been extensively validated as more sensitive early diagnostic markers for AKI than serum creatinine, the concept of subclinical AKI has recently emerged. This evidence concerns the gene LCN2 and acute kidney injury.